Logo

PGDx PlasmaSELECT 64 Panel

Oct 05, 2016

Personal Genome Diagnostics has launched its PlasmaSELECT 64 panel for pan-cancer tumor profiling. The CLIA-validated pan-cancer plasma assay incorporates the company's PARE and Digital Karyotyping technologies combined with VariantDX computational algorithms to identify sequence mutations with exceptional accuracy. The assay looks at genes shown to have biological and functional relevance to aid physicians making treatment decisions, and includes 15 unique biomarkers — 11 of which are associated with active clinical trials, the company said.

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.